EA201290722A1 - Рекомбинантный белок эксендина-4 и его аналога, способ их приготовления и применение - Google Patents

Рекомбинантный белок эксендина-4 и его аналога, способ их приготовления и применение

Info

Publication number
EA201290722A1
EA201290722A1 EA201290722A EA201290722A EA201290722A1 EA 201290722 A1 EA201290722 A1 EA 201290722A1 EA 201290722 A EA201290722 A EA 201290722A EA 201290722 A EA201290722 A EA 201290722A EA 201290722 A1 EA201290722 A1 EA 201290722A1
Authority
EA
Eurasian Patent Office
Prior art keywords
recombinant protein
analogue
preparation
exendin
protein exendin
Prior art date
Application number
EA201290722A
Other languages
English (en)
Other versions
EA023037B1 (ru
Inventor
Сяньхун Бай
Хуа Ту
Сяньчжун Ли
Original Assignee
Бейджинг Дунфан Байотек Ко., Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Бейджинг Дунфан Байотек Ко., Лтд. filed Critical Бейджинг Дунфан Байотек Ко., Лтд.
Publication of EA201290722A1 publication Critical patent/EA201290722A1/ru
Publication of EA023037B1 publication Critical patent/EA023037B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/57563—Vasoactive intestinal peptide [VIP]; Related peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Abstract

Согласно настоящему изобретению предложен рекомбинантный белок эксендина-4 и его аналога, способ их приготовления и применения. Указанный рекомбинантный белок получают путем слияния эксендина-4 или его аналога с Fc-фрагментом IgG2 человека через линкерный пептид. Предложенный рекомбинантный белок имеет более высокую стабильность, более длительное время полужизни в сыворотке и может быть использован для лечения диабета и ожирения.
EA201290722A 2010-06-11 2011-06-10 Рекомбинантный белок эксендина-4 и его аналога, способ их приготовления и применение EA023037B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201010205166A CN101891823B (zh) 2010-06-11 2010-06-11 一种Exendin-4及其类似物融合蛋白
PCT/CN2011/075604 WO2011153965A1 (zh) 2010-06-11 2011-06-10 Exendin-4及其类似物的融合蛋白，其制备和应用

Publications (2)

Publication Number Publication Date
EA201290722A1 true EA201290722A1 (ru) 2013-05-30
EA023037B1 EA023037B1 (ru) 2016-04-29

Family

ID=43101193

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201290722A EA023037B1 (ru) 2010-06-11 2011-06-10 Рекомбинантный белок эксендина-4 и его аналога, способ их приготовления и применение

Country Status (9)

Country Link
US (1) US8889619B2 (ru)
EP (1) EP2581389B1 (ru)
JP (1) JP5865359B2 (ru)
KR (1) KR101530065B1 (ru)
CN (1) CN101891823B (ru)
EA (1) EA023037B1 (ru)
ES (1) ES2597962T3 (ru)
SI (1) SI2581389T1 (ru)
WO (1) WO2011153965A1 (ru)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101891823B (zh) 2010-06-11 2012-10-03 北京东方百泰生物科技有限公司 一种Exendin-4及其类似物融合蛋白
CN102552883B (zh) * 2010-12-09 2014-02-19 天津药物研究院 一种多肽复合物、药物组合物、其制备方法和应用
CN102558362A (zh) * 2012-02-17 2012-07-11 东莞金朗生物科技有限公司 一种用于治疗糖尿病的融合蛋白及其制备方法
CN103130889A (zh) * 2012-06-15 2013-06-05 中国药科大学 一种Exendin-4类似物及其制备方法和应用
CN102827270A (zh) * 2012-09-13 2012-12-19 无锡和邦生物科技有限公司 一种聚乙二醇化艾塞那肽衍生物及其用途
UA116217C2 (uk) 2012-10-09 2018-02-26 Санофі Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
LT2934568T (lt) 2012-12-21 2018-02-12 Sanofi Dvigubi glp1/gip arba trigubi glp/gip/gliukagono agonistai
CN103204944B (zh) * 2013-03-26 2014-05-28 江苏健德生物药业有限公司 用于治疗糖尿病的长效免疫融合蛋白
TW201609799A (zh) 2013-12-13 2016-03-16 賽諾菲公司 雙重ｇｌｐ－１／ｇｉｐ受體促效劑
EP3080149A1 (en) 2013-12-13 2016-10-19 Sanofi Dual glp-1/glucagon receptor agonists
EP3080150B1 (en) 2013-12-13 2018-08-01 Sanofi Exendin-4 peptide analogues as dual glp-1/gip receptor agonists
TW201609796A (zh) 2013-12-13 2016-03-16 賽諾菲公司 非醯化之艾塞那肽－４（ｅｘｅｎｄｉｎ－４）胜肽類似物
TW201625670A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
TW201625669A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
TW201625668A (zh) 2014-04-07 2016-07-16 賽諾菲公司 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
US9932381B2 (en) 2014-06-18 2018-04-03 Sanofi Exendin-4 derivatives as selective glucagon receptor agonists
CN104558198A (zh) * 2014-07-25 2015-04-29 成都贝爱特生物科技有限公司 GLP-1类似物和amylin类似物的融合蛋白制备及其用途
CN105801705B (zh) * 2014-12-31 2019-05-24 天境生物科技(上海)有限公司 含胰高血糖素样肽-1和免疫球蛋白杂合Fc的融合多肽及其用途
AR105319A1 (es) 2015-06-05 2017-09-27 Sanofi Sa Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
AR105284A1 (es) 2015-07-10 2017-09-20 Sanofi Sa Derivados de exendina-4 como agonistas peptídicos duales específicos de los receptores de glp-1 / glucagón
CN105753963B (zh) * 2016-04-13 2019-08-30 中国药科大学 高活性艾塞那肽类似物及其医药应用
CN106046176B (zh) * 2016-08-16 2019-09-10 中国药科大学 一种高活性长效降糖融合蛋白及其制备方法与医药用途
US11359001B2 (en) 2016-12-09 2022-06-14 Akston Biosciences Corporation Insulin-Fc fusions and methods of use
KR102194644B1 (ko) * 2018-04-26 2020-12-24 주식회사 굳티셀 신규한 융합 단백질 및 이를 포함하는 암의 예방 또는 치료용 약학적 조성물
JP7417277B2 (ja) 2018-06-29 2024-01-18 アクストン バイオサイエンシズ コーポレーション 超長期作用性インスリン－ｆｃ融合タンパク質および使用方法
US11267862B2 (en) 2018-06-29 2022-03-08 Akston Biosciences Corporation Ultra-long acting insulin-Fc fusion proteins and methods of use
JP7221385B2 (ja) 2018-10-30 2023-02-13 リウ、チアンニン Ｇｌｐ－１受容体アゴニスト活性を有するｇｌｐ－１ポリペプチドおよびその使用
CN109394681B (zh) * 2018-11-06 2020-03-17 北京东方百泰生物科技有限公司 一种含有Exendin-4 Fc融合蛋白的注射制剂
CN110151980B (zh) * 2019-06-30 2022-12-09 中国药科大学 Glp-1受体激动剂融合蛋白在制备预防或治疗高血脂药物中的应用
BR112022002962A2 (pt) 2019-08-16 2022-07-05 Applied Molecular Transport Inc Composições, formulações e produção e purificação de interleucina
SI4073098T1 (sl) 2019-12-19 2023-12-29 Akston Biosciences Corporation Ultra dolgo delujoči inzulin-fc fuzijski proteini in postopki uporabe
US11186623B2 (en) 2019-12-24 2021-11-30 Akston Bioscience Corporation Ultra-long acting insulin-Fc fusion proteins and methods of use
BR112022020486A2 (pt) 2020-04-10 2023-01-17 Akston Biosciences Corp Imunoterapia específica de antígeno para proteínas de fusão de covid-19 e métodos de uso
US11192930B2 (en) 2020-04-10 2021-12-07 Askton Bioscences Corporation Ultra-long acting insulin-Fc fusion protein and methods of use
US11198719B2 (en) 2020-04-29 2021-12-14 Akston Biosciences Corporation Ultra-long acting insulin-Fc fusion protein and methods of use
US11667689B2 (en) 2021-07-23 2023-06-06 Akston Biosciences Corporation Insulin-Fc fusion proteins and methods of use to treat cancer
CN113801853B (zh) * 2021-11-19 2022-03-15 山东兴瑞生物科技有限公司 Exendin-4融合基因修饰的MSC及其应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1076066A1 (en) * 1999-07-12 2001-02-14 Zealand Pharmaceuticals A/S Peptides for lowering blood glucose levels
PL209550B1 (pl) 2000-12-07 2011-09-30 Lilly Co Eli Heterogenne białko fuzyjne, kompozycja farmaceutyczna do leczenia pacjentów z cukrzycą insulinoniezależną i kompozycja do leczenia pacjentów z otyłością
US6900292B2 (en) 2001-08-17 2005-05-31 Lee-Hwei K. Sun Fc fusion proteins of human erythropoietin with increased biological activities
AU2003268621B2 (en) * 2002-10-02 2009-01-15 Zealand Pharma A/S Stabilized exendin-4 compounds
CN101974090B (zh) 2003-06-12 2015-06-17 伊莱利利公司 Glp-1类似物融合蛋白质
AU2006277557A1 (en) 2005-05-05 2007-02-15 Cadila Healthcare Limited Novel compounds as GPL-I agonists
CA2658673A1 (en) * 2005-07-27 2008-02-01 Gerald J. Prud'homme Composition and method for prevention and treatment of type i and type ii diabetes
CN1935846A (zh) * 2005-09-14 2007-03-28 王庆华 一种用于治疗糖尿病的融合蛋白及其制备方法和应用
JP5119932B2 (ja) * 2008-01-11 2013-01-16 ヤマハ株式会社 鍵盤楽器、ピアノおよび自動演奏ピアノ
CN101891823B (zh) * 2010-06-11 2012-10-03 北京东方百泰生物科技有限公司 一种Exendin-4及其类似物融合蛋白

Also Published As

Publication number Publication date
CN101891823B (zh) 2012-10-03
US8889619B2 (en) 2014-11-18
EP2581389A1 (en) 2013-04-17
EP2581389A4 (en) 2013-10-09
CN101891823A (zh) 2010-11-24
SI2581389T1 (sl) 2017-01-31
EA023037B1 (ru) 2016-04-29
KR101530065B1 (ko) 2015-06-18
WO2011153965A1 (zh) 2011-12-15
ES2597962T3 (es) 2017-01-24
BR112012029689A2 (pt) 2019-10-15
EP2581389B1 (en) 2016-07-20
JP5865359B2 (ja) 2016-02-17
JP2013531488A (ja) 2013-08-08
US20130142795A1 (en) 2013-06-06
KR20120127729A (ko) 2012-11-23

Similar Documents

Publication Publication Date Title
EA201290722A1 (ru) Рекомбинантный белок эксендина-4 и его аналога, способ их приготовления и применение
PE20211272A1 (es) POLIPEPTIDOS DE IL-22 Y PROTEINAS DE FUSION DE IL-22 Fc Y METODOS DE USO
CY1121632T1 (el) Η rv2386c πρωτεϊνη φυματιωσης, συνθεσεις και χρησεις αυτης
MX2014000054A (es) Moleculas de union anti-alfa sinucleina.
SV2017005548A (es) Proteinas de fusion
EA201590525A1 (ru) Слитые белки для лечения метаболического синдрома
EA201290964A1 (ru) Пептидные конъюгаты агонистов рецептора glp-1 и их применение
IN2015DN01115A (ru)
EA201270775A1 (ru) Связывающие сывороточный альбумин молекулы
EA202090216A2 (ru) Связывающие сывороточный альбумин домены фибронектина iii типа
DOP2014000083A (es) Inmunoenlazadores dirigidos contra el tnf
TR201905619T4 (tr) Alerji aşısı olarak peptit taşıyıcı füzyon proteinleri.
EA201490745A1 (ru) Полипептиды антител, которые вызывают антагонизм cd40l
EA201691304A1 (ru) АНТАГОНИСТЫ НЕОНАТАЛЬНЫХ Fc-РЕЦЕПТОРОВ (FcRn) И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
EA201400568A1 (ru) Альбуминсвязывающие антитела и их связывающие фрагменты
EA201590011A1 (ru) Пептидные аналоги эксендина-4
EA201490070A1 (ru) Коантагонисты глюкагонового рецептора/glp-1-рецептора
WO2013075066A3 (en) Variant serum albumin with improved half -life and other properties
EA201690606A1 (ru) Аналоги глюкагона
EA201590910A1 (ru) Белки на основе структурного домена фибронектина, связывающие pcsk9
EA201591700A1 (ru) Гибридные белки апелина и их применение
EA201270769A1 (ru) Антитела к cgrp
EA201000018A1 (ru) Лиофилизированные лекарственные формы иммуноглобулинов и способы их получения
UY30324A1 (es) Proteinas de fusion del rage, formulaciones y métodos de uso
CL2013001279A1 (es) Anticuerpo humano aislado o fragmento de union a antigeno del mismo que se une especificamente y neutraliza la actividad del ligando 1a de tipo tnf humano (htl1a); molecula de acido nucleico que lo codifica; vector de expresion; metodo de produccion; composicion farmaceutica que lo comprende; y su uso.

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ KG MD TJ TM